Ingeneus achieves CE Marking for ophthalmic system

3rd September 2013

Ingeneus is pleased to announce that it has achieved CE Marking for its low cost treatment system for diabetic retinopathy, an eye disease that affects many diabetics. The system was developed by Ingeneus for use by ophthalmic clinicians.

CE Marking signifies that the product complies with the essential health, safety and environmental protection requirements of the European Medical Device Directive.

Ingeneus CEO Richard Walmsley said, “We are excited to receive the CE Mark as it means the system can be used by ophthalmic clinicians throughout Europe. It assures surgeons and patients of the safety and efficacy of our device.

The system provides clinicians with a complete laser solution in the treatment of ocular pathology and provides a new level of performance compared with existing surgery systems,” Richard said.

“It is used in photocoagulation of both anterior and posterior segments of the eye including retinal photocoagulation.”